Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 15/20 | 0.74 |
| ▸ | KIT | P10721 | 11/20 | 0.74 |
| ▸ | AXL | P30530 | 6/20 | 0.61 |
| ▸ | IRAK4 | Q9NWZ3 | 4/20 | 0.61 |
| ▸ | JAK2 | O60674 | 2/20 | 0.61 |
| ▸ | ABL1 | P00519 | 1/20 | 0.59 |
| ▸ | LCK | P06239 | 1/20 | 0.59 |
| ▸ | LYN | P07948 | 1/20 | 0.59 |
| ▸ | MET | P08581 | 1/20 | 0.59 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.59 |
| ▸ | SRC | P12931 | 1/20 | 0.59 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.59 |
| ▸ | KDR | P35968 | 1/20 | 0.59 |
| ▸ | JAK3 | P52333 | 1/20 | 0.59 |
| ▸ | TEK | Q02763 | 1/20 | 0.59 |
| ▸ | KARS1 | Q15046 | 1/20 | 0.59 |
| ▸ | AURKA | O14965 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13963313 | 0.91 | FLT3 (0.76) | FLT3KITAXLIRAK4JAK2 | |
| SCHEMBL12845741 | 0.89 | FLT3 (0.73) | FLT3KITAXLIRAK4JAK2 | |
| SCHEMBL13963314 | 0.89 | FLT3 (0.76) | FLT3KITAXLIRAK4JAK2 | |
| SCHEMBL4040173 | 0.89 | FLT3 (0.72) | FLT3KITAXLIRAK4JAK2 | |
| SCHEMBL14399533 | 0.87 | FLT3 (0.69) | FLT3KITAXLIRAK4JAK2 | |
| SCHEMBL4038957 | 0.87 | FLT3 (0.71) | FLT3KITAXLIRAK4JAK2 | |
| SCHEMBL4037409 | 0.86 | FLT3 (1.00) | FLT3KITAXLIRAK4JAK2 | |
| SCHEMBL12780751 | 0.85 | FLT3 (0.69) | FLT3KITAXLIRAK4JAK2 | |
| SCHEMBL4038815 | 0.85 | FLT3 (0.66) | FLT3KITAXLIRAK4JAK2 | |
| SCHEMBL2088252 | 0.82 | FLT3 (0.76) | FLT3KITAXLIRAK4JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107531705-B | Bicyclic ketone sulfonamide compounds | 美国安进公司 | 2020-09-18 | — | — | CN | disclosed |
| CN-107531705-B | Bicyclic ketone sulfonamide compounds | 美国安进公司 | 2020-09-18 | — | — | CN | disclosed |
| US-10472356-B2 | Bicyclic ketone sulfonamide compounds | AMGEN INC. (US) | 2019-11-12 | — | — | US | disclosed |
| US-7902239-B2 | Diaminotriazoles useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-08 | — | — | US | disclosed |
| US-7902239-B2 | Diaminotriazoles useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-08 | — | — | US | disclosed |
| EP-1641801-B9 | BRIDGED N-ARYLSULFONYLPIPERIDINES AS GAMMA-SECRETASE INHIBITORS | SCHERING CORP (US) | 2009-02-25 | — | — | EP | disclosed |
| EP-1562589-B1 | DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMA (US) | 2009-01-07 | — | — | EP | disclosed |
| EP-1562589-B1 | DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMA (US) | 2009-01-07 | — | — | EP | disclosed |
| EP-1641801-B1 | BRIDGED N-ARYLSULFONYLPIPERIDINES AS GAMMA-SECRETASE INHIBITORS | SCHERING CORP (US) | 2008-07-16 | — | — | EP | disclosed |
| US-7368457-B2 | Bridged N-arylsulfonylpiperidines as gamma-secretase inhibitors | SCHERING CORPORATION (US) | 2008-05-06 | — | — | US | disclosed |
| US-20010056189-A1 | Pyrazole substituted hydroxamic acid derivatives as cyclooxxgenase-2 and 5- lipoxygenase inhibitors | TALLEY JOHN J (US) | 2001-12-27 | — | — | US | disclosed |
| EP-0995747-A1 | Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors | G.D. SEARLE & CO. (US) | 2000-04-26 | — | — | EP | disclosed |
| EP-0828736-A1 | SUBSTITUTED SULFONYLPHENYLHETEROCYCLES AS CYCLOOXYGENASE-2 AND 5-LIPOXYGENASE INHIBITORS | G.D. SEARLE & CO. (US) | 1998-03-18 | — | — | EP | disclosed |
| EP-0828718-A1 | HETEROCYCLO SUBSTITUTED HYDROXAMIC ACID DERIVATIVES AS CYCLOOXYGENASE-2 AND 5-LIPOXYGENASE INHIBITORS | G.D. SEARLE & CO. (US) | 1998-03-18 | — | — | EP | disclosed |
| US-5643933-A | Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors | G. D. SEARLE & CO. (US) | 1997-07-01 | — | — | US | disclosed |
| WO-1996038418-A1 | HETEROCYCLO SUBSTITUTED HYDROXAMIC ACID DERIVATIVES AS CYCLOOXYGENASE-2 AND 5-LIPOXYGENASE INHIBITORS | G.D. SEARLE & CO. (US) | 1996-12-05 | — | — | WO | disclosed |
| WO-1996038442-A1 | SUBSTITUTED SULFONYLPHENYLHETEROCYCLES AS CYCLOOXYGENASE-2 AND 5-LIPOXYGENASE INHIBITORS | G.D. SEARLE & CO. (US) | 1996-12-05 | — | — | WO | disclosed |
| US-5356862-A | Herbicidal sulfonylureas | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1994-10-18 | — | — | US | disclosed |
| EP-0511993-A1 | HERBICIDAL SULFONYLUREAS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-11-11 | — | — | EP | disclosed |
| WO-1991010668-A1 | HERBICIDAL SULFONYLUREAS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10472356-B2 | Bicyclic ketone sulfonamide compounds | TRPV1, TRPA1, KCNJ11 | FLT3 2540/4885KIT 3105/4885AXL 3170/4885 |
| US-20010056189-A1 | Pyrazole substituted hydroxamic acid derivatives as cyclooxxgenase-2 and 5- lipoxygenase inhibitors | ALOX5, ALOX15, ALOX12 | FLT3 2658/4885KIT 2583/4885AXL 3662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.